How to manage waldenstrom's macroglobulinemia in 2024.
Grunenberg A, Buske C.
Cancer Treat Rev. 2024 Apr;125:102715. doi: 10.1016/j.ctrv.2024.102715. Epub 2024 Mar 5.
Waldenstrom's macroglobulinemia.
McKenna JA.
Clin J Oncol Nurs. 2002 Sep-Oct;6(5):283-6. doi: 10.1188/02.CJON.283-286.
Waldenstrom's macroglobulinemia.
Gertz MA, Fonseca R, Rajkumar SV.
Oncologist. 2000;5(1):63-7. doi: 10.1634/theoncologist.5-1-63.
Diagnosis and Management of Waldenstrom's Macroglobulinemia.
Treon SP, Sarosiek S, Castillo JJ.
Hematol Oncol. 2025 Jun;43 Suppl 2:e70071. doi: 10.1002/hon.70071.
Waldenstrom's macroglobulinaemia.
[No authors listed]
Lancet. 1985 Aug 10;2(8450):311-2.
Epigenomics in Waldenstrom's macroglobulinaemia.
Sacco A, Fenotti A, Bazzana S, Imberti L, Rossi G, Patterson CJ, Treon SP, Ghobrial IM, Roccaro AM.
Best Pract Res Clin Haematol. 2016 Jun;29(2):156-160. doi: 10.1016/j.beha.2016.08.022. Epub 2016 Sep 25.
New developments in the diagnosis and characterization of Waldenstrom's macroglobulinemia.
García-Sanz R, Hunter ZR, Poulain S, Varettoni M, Owen RG.
Expert Rev Hematol. 2023 Jul-Dec;16(11):835-847. doi: 10.1080/17474086.2023.2270779. Epub 2023 Nov 17.
Managing complications secondary to Waldenstrom's macroglobulinemia.
Pessach I, Dimopoulos MA, Kastritis E.
Expert Rev Hematol. 2021 Jul;14(7):621-632. doi: 10.1080/17474086.2021.1947236. Epub 2021 Jul 2.
[Waldenstrom's disease].
Fernández García E, Fernández Blasco E.
Rev Clin Esp. 1965 Jun 30;97(6):413-5.
Vasoproliferative retinopathy secondary to Waldenstrom's disease.
Espinosa-Barberi G, Galván González FJ, Miranda Fernández S, Viera Peláez D, Medina Rivero F, Marrero Saavedra D.
Arch Soc Esp Oftalmol (Engl Ed). 2019 Feb;94(2):85-89. doi: 10.1016/j.oftal.2018.09.006. Epub 2018 Oct 11.
